English, Article edition: Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients: A Pharmacoeconomic Analysis George Dranitsaris; Mark Vincent; Mark Crowther

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94393
Physical Description
  • article
Language
  • English

Edition details

Title
  • Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients: A Pharmacoeconomic Analysis
Author
  • George Dranitsaris
  • Mark Vincent
  • Mark Crowther
Physical Description
  • article
Notes
  • Objective: In a recent randomised trial (CLOT [Comparison of Low molecular weight heparin versus Oral anticoagulant Therapy for long term anticoagulation in cancer patients with venous thromboembolism]), which evaluated secondary prophylaxis of venous thromboembolism (VTE) in cancer patients, dalteparin reduced the relative risk of recurrent VTEs by 52% compared with oral anticoagulation therapy (p =​ 0.002). A Canadian pharmacoeconomic analysis was conducted to measure the economic value of dalteparin for this indication. Design: The study was conducted from the Canadian healthcare system. The first part of this study utilised the CLOT trial database, from which resource utilisation data were converted into Canadian cost estimates ($Can, year 2005 values). Univariate and multivariate regression analyses were conducted to compare the total cost of therapy between patients randomised to treatment with dalteparin or oral therapy. Health state utilities and treatment preferences were then measured in 24 oncology care providers using the time trade-off technique. Results: When all of the cost components were combined for the entire population (n =​ 676), patients in the dalteparin group had significantly higher overall costs than the control group ($Can4162 vs $Can2003; p < 0.001). The preference assessment revealed that 23 of 24 respondents (96%) selected dalteparin over warfarin, with an associated gain of 0.157 QALYs. When the incremental cost of dalteparin ($Can2159 per patient) was combined with the QALY gain, the findings revealed that dalteparin was associated with a cost of approximately $Can13_800 (95% CI 12_400, 15_100) per QALY gained. Conclusions: Given the practical advantages of dalteparin in terms of convenience, improved efficacy and the acceptable economic value, this analysis suggests that long-term dalteparin therapy is a sound alternative to warfarin for the prevention of recurrent VTEs in patients with cancer.
  • Cancer, Cost-effectiveness, Cost-utility, Dalteparin-sodium, Resource-use, Thromboembolism, Venous-thrombosis, Warfarin, Thromboembolism
  • RePEc:wkh:phecon:v:24:y:2006:i:6:p:593-607
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment